Quantcast
Channel: MassDevice
Viewing all articles
Browse latest Browse all 1713

OncoSec inks deal with Merck to study drug-device therapy for metastatic melanoma

$
0
0

OncoSec MedicalOncoSec Medical (NSDQ:ONCS) said today that it inked a clinical trial collaboration and supply agreement with Merck (NYSE:MRK) to evaluate the combination of its ImmunoPulse IL-12 electroporation device with Merck’s Keytruda therapy in a Phase II clinical trial.

The trial aims to evaluate the drug-device combination in patients with metastatic melanoma – specifically patients who experienced disease progression after previous treatment with an anti-PD-1 therapy.

OncoSec’s electroporation device delivers a sequence of short-duration electrical pulses to increase the cancer cell membrane’s permeability and more efficiently deliver cancer-killing drugs.

Get the full story at our sister site, Drug Delivery Business News.

The post OncoSec inks deal with Merck to study drug-device therapy for metastatic melanoma appeared first on MassDevice.


Viewing all articles
Browse latest Browse all 1713

Trending Articles